Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination antiplatelet therapy: implications for pharmacists.

Robert L Talbert1, Sarah A Spinler, Jean M Nappi

  • 1College of Pharmacy, University of Texas, and Department of Medicine, University of Texas Health Science Center, San Antonio, 78229-3900, USA. talbert@uthscsa.edu

Pharmacotherapy
|October 23, 2002
PubMed
Summary

Suboptimal oral antiplatelet therapy can lead to adverse outcomes in acute coronary syndromes. Recent guideline changes emphasize dual antiplatelet therapy for unstable angina and non-ST-segment elevation myocardial infarction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association.

Stroke·2026
Same author

Clinical Pharmacists and Industry: Guidelines for Professional Interactions.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Reply: Impact of Remdesivir on Heart Rate and Bradycardia Incidence Among Hospitalized Adults With COVID-19.

The Annals of pharmacotherapy·2025
Same author

Preparing NAPLEX-Ready Graduates Requires Collaboration to Optimize Success.

American journal of pharmaceutical education·2025
Same author

Impact of Remdesivir on Heart Rate and Bradycardia Incidence Among Hospitalized Adults With COVID-19.

The Annals of pharmacotherapy·2025
Same author

Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors.

Journal of pharmacy practice·2024

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • National guidelines for managing acute coronary syndromes (ACS) have been updated.
  • Recent evidence from randomized controlled trials (RCTs) influenced these changes.

Observation:

  • Two case reports highlight suboptimal oral antiplatelet therapy.
  • These cases involved patients with unstable angina and non-ST-segment elevation myocardial infarction.

Findings:

  • The American College of Cardiology and American Heart Association revised guidelines in March 2002.
  • Suboptimal therapy occurred when dual antiplatelet drugs were indicated but not administered.

Implications:

  • Pharmacists must be aware of updated antiplatelet and anticoagulant therapy guidelines.

Related Experiment Videos

  • Patient counseling on appropriate antiplatelet drug administration is crucial for optimal ACS management.